Hobart Private Capital LLC Buys 2,979 Shares of Boston Scientific Corporation $BSX

Hobart Private Capital LLC increased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 128.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 5,295 shares of the medical equipment provider’s stock after purchasing an additional 2,979 shares during the quarter. Hobart Private Capital LLC’s holdings in Boston Scientific were worth $569,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after purchasing an additional 1,697,945 shares during the last quarter. Invesco Ltd. increased its position in shares of Boston Scientific by 5.3% during the 1st quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider’s stock valued at $1,677,124,000 after purchasing an additional 834,274 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Boston Scientific by 10.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after purchasing an additional 1,383,524 shares during the last quarter. Amundi increased its position in shares of Boston Scientific by 2.6% during the 1st quarter. Amundi now owns 12,308,715 shares of the medical equipment provider’s stock valued at $1,212,408,000 after purchasing an additional 311,034 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Boston Scientific by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider’s stock valued at $1,139,938,000 after purchasing an additional 460,580 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 1.3%

Shares of NYSE BSX opened at $101.08 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The stock has a market capitalization of $149.78 billion, a P/E ratio of 54.06, a price-to-earnings-growth ratio of 2.37 and a beta of 0.61. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The business has a fifty day moving average price of $101.14 and a 200 day moving average price of $102.00.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The firm’s quarterly revenue was up 20.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on BSX shares. Evercore ISI reaffirmed an “outperform” rating on shares of Boston Scientific in a research report on Wednesday. Raymond James Financial upped their price objective on Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a research report on Thursday, July 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $121.00 price objective on shares of Boston Scientific in a research report on Friday, October 17th. Barclays upped their price objective on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Finally, Wells Fargo & Company increased their price target on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Buy” and an average target price of $123.77.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 170,214 shares of company stock worth $17,548,337. 0.50% of the stock is owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.